dementia - Page 1 | CARLAT PUBLISHING

Research Update

Olive Oil Linked to Lower Dementia Mortality

January 1, 2026

Jaime A.B. Wilson, PhD, ABN, ABPP, MSCP. Dr. Wilson has no financial relationships with companies related to this material.

Research Update

Are We Missing a Potentially Reversible Contributor to Cognitive Impairment?

January 1, 2026

Susan L. Siegfreid, MD

Susan L. Siegfreid, MD. Dr. Siegfreid has no financial relationships with companies related to this material.

Could that “dementia” be liver-related and reversible? A large VA study reveals how often cirrhosis goes undiagnosed in older adults with cognitive decline and why checking a simple fibrosis score might change your diagnosis and your treatment plan.

“Where’s My Boat?” — Treating Agitation in Dementia

September 1, 2025

Daniel Carlat, MD

We’re often told antipsychotics are a last resort for agitation in dementia. And that’s true—they are. But when you do reach that last resort, you need to know how to use it—and how to talk about it with families.

Fact Sheet

Vascular Dementia: Diagnosis and Treatment

August 2, 2025

Rehan Aziz, MD

Dr. Aziz has no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Vascular dementia (VaD) is caused by cerebrovascular compromise, most frequently as the result of strokes.

Research Update

Diagnosing Mild Cognitive Impairment: Neuropsych Testing and MoCA Go Head to Head

July 1, 2024

Susan L. Siegfreid, MD

Susan L. Siegfreid, MD. Dr. Siegfreid has no financial relationships with companies related to this material.

This study compares the MoCA to neuropsychological testing in identifying mild cognitive impairment.

Clinical Update

Lecanemab Breaks Thin Ground in Dementia

May 1, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Concerns arise regarding lecanemab’s efficacy, high cost, and a notable risk of cerebral edema.

shutterstock_2417738561_PeopleImages.com_Yuri A.png

COMMENTARY

Insights About a Rare Transmissible Form of Alzheimer's Disease

February 9, 2024

Rehan Aziz, MD

Researchers found a connection between Alzheimer's disease and the use of contaminated growth hormone from human cadavers, highlighting the importance of understanding Alzheimer's pathology for better treatment development.

Research Update